EP1706174A2 - Method and apparatus for modifying delivery of a therapy in response to onset of sleep - Google Patents
Method and apparatus for modifying delivery of a therapy in response to onset of sleepInfo
- Publication number
- EP1706174A2 EP1706174A2 EP04812801A EP04812801A EP1706174A2 EP 1706174 A2 EP1706174 A2 EP 1706174A2 EP 04812801 A EP04812801 A EP 04812801A EP 04812801 A EP04812801 A EP 04812801A EP 1706174 A2 EP1706174 A2 EP 1706174A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- state
- response
- patient
- minute ventilation
- onset
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 92
- 230000004044 response Effects 0.000 title claims abstract description 73
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 54
- 238000009423 ventilation Methods 0.000 claims description 217
- 238000001514 detection method Methods 0.000 claims description 39
- 230000002459 sustained effect Effects 0.000 claims description 21
- 230000007704 transition Effects 0.000 claims description 18
- 230000035939 shock Effects 0.000 description 70
- 230000000694 effects Effects 0.000 description 61
- 230000001746 atrial effect Effects 0.000 description 58
- 230000002861 ventricular Effects 0.000 description 33
- 206010003658 Atrial Fibrillation Diseases 0.000 description 27
- 206010003668 atrial tachycardia Diseases 0.000 description 22
- 238000002633 shock therapy Methods 0.000 description 20
- 230000037007 arousal Effects 0.000 description 18
- 210000000115 thoracic cavity Anatomy 0.000 description 17
- 238000013194 cardioversion Methods 0.000 description 15
- 208000001871 Tachycardia Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000005241 right ventricle Anatomy 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 9
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 210000005245 right atrium Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 210000003748 coronary sinus Anatomy 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000004020 conductor Substances 0.000 description 5
- 230000037081 physical activity Effects 0.000 description 5
- 230000006794 tachycardia Effects 0.000 description 5
- 210000002620 vena cava superior Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 206010061592 cardiac fibrillation Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- 206010047302 ventricular tachycardia Diseases 0.000 description 3
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 2
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011367 less aggressive therapy Methods 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000037074 physically active Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005316 response function Methods 0.000 description 2
- 230000008667 sleep stage Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36521—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure the parameter being derived from measurement of an electrical impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36542—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by body motion, e.g. acceleration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/37—Monitoring; Protecting
- A61N1/3702—Physiological parameters
Definitions
- This invention relates generally to medical devices, and, more particularly to implantable medical devices for providing various types of therapies to patients.
- Implantable cardioverter defibrillators are capable of detecting cardiac an-hythmias and delivering electrical stimulation therapies to terminate arrhythmias. Tachycardia may be terminated by anti-tachycardia pacing therapies or high- voltage cardioversion shocks.
- Fibrillation may be terminated by high- oltage def ⁇ brillation shocks.
- These high- voltage shocks which are referred to inclusively herein as “cardioversion/defibrillation shocks,” can be life-saving to a patient but can be very painful.
- Atrial arrhythmias such as atrial tachycardia (AT) and atrial fibrillation (AF)
- AT atrial tachycardia
- AF atrial fibrillation
- atrial cardioversion/defibrillation therapies employing high-voltage shocks may be programmed to be disabled in an ICD, or programmed to be delivered after the AT/AF episode has been detected for a sustained period of time, for example 2 hours or longer.
- Atrial arrhythmia detection algorithms may remain enabled because a physician may want to monitor for the presence of AT and AF for the purposes of managing medical therapies, such as anti- coagulation therapy and anti-arrhythmic drugs.
- non-painful, antl ⁇ tachycardia pacing therapies may be delivered in an attempt to terminate a detected atrial arrhythmia. If these less aggressive therapies fail, however, or if all atrial arrhythmia therapies are disabled, the atrial arrhythmia may be sustained for long periods of time. During sustained AT/AF episodes, blood stasis in the atria can result in the formation of clots or thrombus.
- Model 7250 dual chamber ICD revealed that atrial fibrillation (AF) is a co-existent arrhythmia with ventricular tachycardia (VT) or ventricular fibrillation (VF) in a significant patient population. Approximately 18% of all VF episodes and 3% of all NT episodes were accompanied by recent onset AF or AT. Stein ELM et al., J Am Coll Cardiol Proc, 1999. The termination of AT/AF using treatment modalities that are acceptable and tolerable to the patient is therefore desirable over sustained periods of untreated AT/AF. Atrial arrhytlimia treatments that are tolerable to the patient are needed in order to increase patient acceptance and physician use of such therapies. In U.S. Pat. No.
- an automatic atrial defibrillator having the ability to determine whether the patient is likely to be asleep senses the occurrence of atrial fibrillation and delivers defibrillation pulses in response thereto.
- Def ⁇ brillation pulses which are at energy levels which would normally be painful to the patient are delivered only in response to occurrences of atrial fibrillation while the patient is determined to be asleep.
- Defibrillation pulses at lower, non-painful levels may be delivered while the patient is determined not to be asleep. Detection of the fact that the patient is sleeping can be accomplished using a real time clock, which may be used in conjunction with a physical activity sensor, and/or a posture sensor.
- a timekeeping method for sleep detection is limited when the patient changes his/her bed time and/or wake time, travels to a different time zone, etc. Detection of sleep based on time of day, even when combined with activity and/or posture, may not discriminate night time inactivity from a period of deep sleep, when a patient's perception of a normally painful defibrillation shock is most likely to be suppressed. In currently available ICD's, atrial defibrillation shocks may be scheduled to occur in the middle of the night, e.g. s 2:00 A.M., in a patient having persistent AF.
- the patient may be aware that a defibrillation shock is scheduled to occur at a particular time during the night and, in anticipation of the impending shock, remain awake.
- a need remains, therefore, for a method and apparatus for delivering therapies that are uncomfortable or painful to a patient during a period of deep sleep such that the discomfort perceived by the patient is suppressed.
- Fig. 1 is a diagram of one embodiment of an implantable medical device (IMD) system including a cardiac pacemaker, an atrial lead, and a ventricular lead implanted in a patient
- Fig. 2 is a diagram of one embodiment of the cardiac pacemaker of Fig. 1, wherein the pacemaker produces pacing pulses delivered to a heart of the patient of Fig. 1 via the atrial lead and the ventricular lead
- Figs. IMD implantable medical device
- FIG. 3A-3D in combination form a flow chart of one embodiment of a method for determining an onset of sleep in a patient having an implantable medical device (e.g., the pacemaker of Figs. 1-2) implanted therein;
- Fig. 4 is a flow chart of one embodiment of a method for providing a therapy to the patient, wherein the method involves determining an onset of sleep in the patient;
- Fig. 5 A is a histogram of minute ventilation values of a patient obtained via minute ventilation sensing circuitry over a 24-hour period;
- Fig. 5B is a histogram of standard deviations of the minute ventilation values used to form the histogram of Fig. 4 A and received within 1 -minute time windows;
- Fig. 5 A is a histogram of minute ventilation values of a patient obtained via minute ventilation sensing circuitry over a 24-hour period;
- Fig. 5B is a histogram of standard deviations of the minute ventilation values used to form the histogram of Fig.
- FIG. 6 is a graph of standard deviation values "MV Stdev Long” and “MV Stdev Short” calculated using minute ventilation values produced during 2-second time intervals and indicative of the minute ventilation of a patient; and Fig. 7 is a graph of a standard deviation value "MV Stdev Long” calculated using minute ventilation values produced during 2-second time intervals and indicative of the minute ventilation of a patient.
- Figure 8 is an illustration of an alternative embodiment of an implantable medical device system including an implantable cardioverter defibrillator.
- Figure 9 is a diagram of one embodiment of the ICD of Figure 8.
- Figure 10 is a flow chart summarizing the steps performed in one embodiment of a method for controlling the delivery of high-energy shock pulses for treating atrial arrhythmias pending the detection of sleep.
- Figure 11 is a flow chart summarizing the steps performed in an alternative embodiment of a method for controlling the delivery of high-energy shock pulses for treating atrial arrhythmias pending the detection of sleep.
- Figure 12 is a flow chart providing additional details included in one embodiment of a step for detecting arousal included in the method of Figure 11.
- Figure 13 is a flow chart summarizing the steps performed in yet another embodiment of a method for controlling the delivery of high-energy shock pulses for treating atrial arrhythmias pending the detection of sleep. While the invention is susceptible to various modifications and alternative fonns, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail.
- FIG. 1 is a diagram of one embodiment of an implantable medical device (IMD) system 100 including a cardiac pacemaker 102, an atrial lead 104, and a ventricular lead 106 implanted in a patient 108.
- IMD implantable medical device
- the pacemaker 102 produces electrical pulses (i.e., pacing pulses) that stimulate a heart 110 of the patient 108.
- One end of the atrial lead 104 is electrically coupled to the pacemaker 102, the other end of the atrial lead 104 extends through a vein 112 into a right atrium of the heart 110.
- One end of the ventricular lead 106 is electrically coupled to the pacemaker 102, the other end of the ventricular lead 106 extends through the vein 112 and into a right ventricle of the heart 110.
- Electrically conductive electrodes attached to the ends of the atrial lead 104 and the ventricular lead 106 located within the heart 110 are used to deliver pacing pulses to the heart 110, and to receive intrinsic electrical signals present within the heart 110.
- the pacemaker 102 may be housed within a hermetically sealed, biologically inert outer canister or housing. At least a portion of the housing may be electrically conductive, and may serve as an electrode in pacing and/or sensing circuits of the pacemaker 102.
- the IMD system 100 of Fig. 1 also includes a programming unit 114 for programming the pacemaker 102.
- a programming head 116 is connected to the programming unit 114, and enables two-way communication between the programming unit 114 and the pacemaker 102 as indicated in Fig. 1.
- the programming head 116 may include a radio frequency (RF) antenna, and may send RF signals to, and receive RF signals from, the pacemaker 102.
- RF radio frequency
- the pacemaker 102 produces pacing pulses delivered to the heart 110 of the patient 108 (Fig. 1) via the atrial lead 104 and the ventricular lead 106.
- the pacemaker 102 includes lead interface circuitry 200, pacing output circuitry 202, a central processing unit (CPU) 204, a memory 206, timing/pacing control circuitry 208, a minute ventilation (MN) sensing circuit 210, an activity sensing circuit 212, a telemetry unit 214, and an antenna 216.
- CPU central processing unit
- MN minute ventilation
- the atrial lead 104 and the ventricular lead 106 conduct pacing pulses produced by the pacemaker 102 to the heart 110 of the patient 108 (Fig. 1), and also conduct intrinsic electrical signals present within the heart 110 to the pacemaker 102.
- the lead interface circuitry 200 forms an electrical interface between the atrial lead 104 and the ventricular lead 106 and other components of the pacemaker 102.
- the pacing output circuitry 202 produces atrial and ventricular pacing pulses for stimulating the heart 110.
- the CPU 204 executes instructions stored in the memory 206, and controls the operations of other components of the pacemaker 102.
- the pacemaker 102 of Figs. 1 and 2 may be termed a "dual-chamber" pacemaker.
- the pacemaker 102 may be programmable to operate in one or more of several different predefined operating modes, including a "demand" mode. In the “demand mode,” the pacemaker 102 senses intrinsic electrical signals present within the heart 110 of the patient 108 (Fig. 1), and produces pacing pulses only when the pacing pulses are needed.
- the pacemaker 102 may be programmed with a value indicating whether or not the "demand” mode is enabled, a "low rate limit” value indicating a low limit of an intrinsic beat rate of the heart 110 of the patient 108 (Fig. 1), and an "atrioventricular (AV) interval” value indicating a maximum length of time be ⁇ ween an atrial contraction or "atrial beat” and a subsequent ventricular contraction or “ventricular beat.”
- the timing/pacing control circuitry 208 may include various registers for storing values indicative of programmed parameters of the pacemaker 102, and various counters 5 for performing timing functions.
- the CPU 204 may store programmed "demand” mode, "low rate limit,” and "AV interval” values in one or more registers of the timing/pacing control circuitry 208.
- the timing/pacing control circuitry 208 includes sensing circuitry that receives and detects intrinsic electrical signals present within the heart 110 of the patient 108 (Fig. 1). 10 Specifically, the sensing circuitry of the timing/pacing control circuitry 208 receives a first electrical signal indicative of an intrinsic contraction of the right atrium via the atrial lead 104. In response the first electrical signal, the sensing circuitry may generate an "atrial beat" signal within the timing/pacing control circuitry 208.
- the timing/pacing control 15 circuitry 208 may provide an "atrial trigger” signal to the pacing output circuitry 202 if a frequency at which the "atrial beat” signals are generated is below the programmed “low rate limit.” In other words, the timing/pacing control circuitry 208 may provide an "atrial trigger” signal to the pacing output circuitry 202 if the intrinsic beat rate of the heart 110 (Fig. 1) falls below the programmed "low rate limit.” In response to the atrial trigger ( 20 signal, the pacing output circuitry 202 may produce an atrial pacing pulse, and provide the atrial pacing pulse to the right atrium of the heart 110 (Fig. 1) via the atrial lead 104.
- the atrial pacing pulse typically causes the right and left atria of the heart 110 to contract in unison.
- the sensing circuitry of the timing/pacing control circuitry 208 also receives a 25 second electrical signal indicative of an intrinsic contraction of the right ventricle via the ventricular lead 106. In response the second electrical signal, the sensing circuitry may generate a "ventricular beat” signal within the timing/pacing control circuitry 208. If the "demand" mode of the pacemaker 102 is enabled and the "ventricular beat" signal is not generated within the programmed "AV interval” following an "atrial beat” signal, the 30 timing/pacing control circuitry 208 may provide a "ventricular trigger" signal to the pacing output circuitry 202.
- the pacing output circuitry 202 may produce a ventricular pacing pulse, and provide the ventricular pacing pulse to the right ventricle of the heart 110 (Fig. 1) via the ventricular lead 106.
- the ventricular pacing pulse typically causes the right and left ventricles of the heart 110 to contract in unison.
- the minute ventilation sensing circuit 210 produces a minute ventilation output signal indicative of the minute ventilation of the patient 108 (Fig. 1).
- the minute ventilation sensing circuit 210 produces the minute ventilation output signal dependent upon changes of electrical impedance in a thoracic cavity of the patient 108, and the minute ventilation output signal constitutes digital values indicative of the minute ventilation of the patient 108 produced at regular time intervals.
- the minute ventilation output signal may be a continuous analog signal.
- electrically conductive electrodes are attached to the ends of the atrial lead 104 and the ventricular lead 106 (Fig. 1), and at least a portion of the outer canister or housing of the pacemaker 102 (Figs. 1-2) may be electrically conductive.
- the minute ventilation sensing circuit 210 may deliver an electrical current excitation signal between a first electrode, at the end of either the atrial lead 104 or the ventricular lead 106, and the outer canister or housing of the pacemaker 102.
- the cu ⁇ ent excitation signal may include, for example, current pulses delivered at a predetermined rate (e.g., 16 pulses per second, or 16 Hertz).
- An electrical voltage signal may be measured between a second electrodes, at the end of the atrial lead 104 or the ventricular lead 106, and the outer canister or housing of the pacemaker 102.
- a thoracic impedance signal may be generated by dividing a magnitude of the electrical voltage signal by a magnitude of the electrical current excitation signal.
- the thoracic impedance signal is a voltage signal having three main components: a direct cu ⁇ ent (d.c.) offset voltage, a cardiac component resulting from the function of the heart 110 of the patient 108 (Fig. 1), and a respiratory component.
- the minute ventilation sensing circuit 210 may include, for example, a bandpass filter (e.g., having a passband of, for example, 0.05Hz to 0.8 Hz), and the thoracic impedance signal may be passed through the bandpass filter to substantially remove the d.c. offset voltage and the cardiac component. The resulting "filtered" thoracic impedance signal, emerging at an output of the bandpass filter, substantially comprises the respiratory component.
- the minute ventilation sensing circuit 210 may also include sample-and-hold circuitry and comparison circuitry (not shown). As described above, the minute ventilation sensing circuit 210 may deliver cu ⁇ ent pulses at a predetermined rate (e.g., 16 Hz).
- the predetermined rate defines a time interval between pulses, refe ⁇ ed to herein as a "cycle time.”
- the minute ventilation sensing circuit 210 delivers a cu ⁇ ent pulse.
- the sample-and-hold circuitry may sample the filtered thoracic impedance signal at the beginning of each cycle time, thereby acquiring a
- the comparison circuitry may compare the "cu ⁇ ent" value of the filtered thoracic impedance signal to a "previous” value of the filtered thoracic impedance signal, acquired by the sample-and-hold circuitry at the beginning of the preceding cycle time.
- the comparison circuitry may produce an analog "difference" voltage equal to a difference between the "current" value of the filtered thoracic impedance signal and the "previous” value of the thoracic impedance signal.
- the minute ventilation sensing circuit 210 may also include analog-to-digital conversion circuitry, summing circuitry, and a register (not shown). The analog-to-digital conversion circuitry may convert the analog difference voltage produced by the comparison circuitry to a digital "count" value representing the difference between the
- the summing circuitry may sum the digital "count” values produced by the analog-to-digital conversion circuitry over a predetermined number of the cycle times (i.e., over a predetermined time interval). The resulting sum of the digital "count” values, acquired over the predetermined time interval, is refe ⁇ ed to herein as a "minute ventilation count value.”
- a digital "minute ventilation count value" is thus present in the register at the end of each predetermined time interval, wherein the digital "minute ventilation count value” is indicative of the minute ventilation of the patient 108 (Fig. 1).
- the digital "minute ventilation count value" (i.e., the contents of the register) may be provided to the CPU 204 (e.g., via an inte ⁇ upt or programmed input/output mechanism), and the register may be cleared.
- the minute ventilation sensing circuit 210 may deliver cu ⁇ ent pulses at a rate of 16 Hz as described above.
- the summing circuitry may sum 32 of the digital "count" values produced by the analog-to-digital conversion circuitry over a predetermined 2-second time interval.
- the digital "minute ventilation count value" (i.e., the contents of the register) may be provided to the CPU 204 (e.g., via an interrupt or programmed input/output mechanism), and the register may be cleared.
- the minute ventilation output may be a continuous analog waveform indicative of the minute ventilation of the patient 108 (Fig. 1).
- the continuous analog waveform may be sampled at regular intervals, and the analog samples may be converted to corresponding digital values.
- the activity sensing circuit 212 senses movement or physical activity of the patient
- the activity sensing circuit 212 may include, for example, an element producing an electrical signal when subjected to mechanical stress (e.g., a piezoelectric crystal), and a mechanical apparatus for subjecting the element to mechanical stress when the patient 108 moves or is physically active.
- the element and the mechanical apparatus for subjecting the element to mechanical stress when the patient 108 moves or is physically active may form, for example, an accelerometer (not shown).
- the accelerometer may produce an output signal.
- the activity sensing circuit 212 may include a piezoelectric sensor bonded to an inner surface of the outer canister or housing of the pacemaker 102 (Figs. 1-2), and the piezoelectric sensor may produce the output signal.
- the activity sensing circuit 212 may include a bandpass filter, and the output signal of the accelerometer or piezoelectric sensor may be coupled to an input of the bandpass filter.
- An output signal produced by the bandpass filter may be compared to a threshold value (e.g., a programmable threshold value). Peaks in the output signal of the bandpass filter which exceed the threshold value, refe ⁇ ed to herein as "activity counts," may indicate movement or physical activity of the patient 108 (Fig. 1) of sufficient magnitude that an increase in pacing rate may be wa ⁇ anted.
- a threshold value e.g., a programmable threshold value
- the activity sensing circuit 212 may include circuitry for summing "activity counts" occurring within predetermined time intervals (e.g., two second time intervals), and a register for storing the sum of the "activity counts.” At the end of each regular time interval, the co ⁇ esponding sum of the "activity counts," contained within the register, constitutes a digital "activity value.” The contents of the register may be provided to the CPU 204 at the end of each regular time interval (e.g., via an interrupt or programmed input/output mechanism), and the register may be cleared. It is noted that there are several known methods for producing measures of movement or physical activity of the patient 108 (Fig.
- the pacemaker 102 is typically programmed with a "high rate limit” value indicating a high limit of an intrinsic beat rate of the heart 110 of the patient 108. If a "rate response" mode of the pacemaker 102 is enabled (e.g., via a programmable parameter), the CPU 204 may execute software instructions stored in the memory 206 that implement the "rate response” mode. In this situation, the CPU 204 may vary the "low rate limit” value and or the "AV interval" value stored in the timing/pacing control circuitry 208, dependent upon the minute ventilation output produced by the MV sensing circuit 210 and/or the activity output produced by the activity sensing circuit 212.
- the CPU 204 may vary the "low rate limit” value and/or the "AV interval” value according to a transfer function (e.g., a programmable transfer function) to achieve a rate response defined by the "low rate limit” value, the "high rate limit” value, and the transfer function.
- a transfer function e.g., a programmable transfer function
- the rate at which the pacing output circuitry 202 produces the atrial pacing pulses is varied between the "low rate limit” and the "high rate limit” dependent upon the minute ventilation output produced by the MV sensing circuit 210 and/or the activity output produced by the activity sensing circuit 212.
- a "target" pacing rate at which pacing output circuitry 202 produces the atrial pacing pulses may be expressed as:
- the "target" pacing rate may be increased from the "low rate limit” by incremental amounts determined by the activity output produced by the activity sensing circuit 212. As long as the activity output produced by the activity sensing circuit 212 indicates activity of the patient 108, the
- target pacing rate may be periodically increased by incremental amounts until the "high rate limit” is reached.
- the activity output produced by the activity sensing circuit 212 indicates activity of the patient 108 has ceased, the "target” pacing rate may be gradually reduced by incremental amounts until the "low rate limit” is reached.
- the rate response function/ may be selected such that the "target" pacing rate is based substantially on the activity output produced by the activity sensing circuit 212 when the patient is relatively inactive, and based substantially on the minute ventilation output produced by the minute ventilation sensing circuit 210 when the patient is relatively active. Any one of several known methods for combining or "blending" outputs of activity sensors and minute ventilation sensors may be employed in generating the "target" pacing rate.
- the telemetry unit 214 is coupled to the antenna 216, and communicates with the programming head 116 (Fig. 1) via antenna 216.
- the antenna 216 may be a radio frequency (RF) antenna, and the telemetry unit 214 may send RF signals to, and receive RF signals from, the programming head 116 (Fig. 1).
- RF radio frequency
- CPU 204 communicates with the programming unit 114 (Fig. 1) via the telemetry unit 214, the antenna 216, and the programming head 116.
- CPU 204 receives values to be stored in memory locations of the memory 206 from the programming unit 114 via the telemetry unit 214.
- the received values may be, for example, the values of programmable parameters, which determine the operation of the pacemaker 102.
- CPU 204 may also use the telemetry unit 214 to transmit values residing in memory locations of the memory 206 to the programming unit 114.
- the transmitted values may be, for example, the values of programmable parameters, which determine the operation of the pacemaker 102, and/or data indicative of sensed parameters of the patient 108 (Fig.l).
- 3A-3D in combination form a flow chart of one embodiment of a method 300 for determining an onset of sleep in a patient (e.g., patient 108 of Fig. 1) having an implantable medical device (e.g., pacemaker 102 of Figs. 1-2) implanted therein.
- the method 300 may be embodied within software residing in the memory 206 (Fig. 2) of the pacemaker 102.
- the CPU 204 (Fig. 2) may carry out the method 300 when executing the software embodying the method 300.
- the method 300 includes a "preliminary" portion 302 and a "recu ⁇ ent" portion 304. During the preliminary portion 302, two minute ventilation threshold values are determined.
- At least some of the steps of the recu ⁇ ent portion 304 are ca ⁇ ied out at predetermined time intervals.
- the minute ventilation threshold values determined during the preliminary portion 302 are used during the recu ⁇ ent portion 304 to determine the onset of sleep in a patient having the implantable medical device implanted therein.
- "minute ventilation values" are received at predetermined time intervals over a predete ⁇ nined period of time.
- ventilation values are indicative of the minute ventilation of the patient having the implantable medical device implanted therein.
- the minute ventilation sensing circuit 210 Fig.
- the minute ventilation sensing circuit 210 delivers cu ⁇ ent pulses at a rate of 16 Hz, thereby defining pulse "cycles” having "cycle times" of 1/16 or 0.0625 seconds.
- the minute ventilation sensing circuit 210 converts an analog difference voltage between a "cu ⁇ ent” value of a thoracic impedance signal, obtained during a "cu ⁇ ent” pulse cycle, and a "previous” value of the thoracic impedance signal, obtained during a pulse cycle preceding the cu ⁇ ent pulse cycle, to a digital "count” value.
- the minute ventilation sensing circuit 210 sums 32 of the digital "count” values produced by the analog-to-digital conversion circuitry in a register over a predefined 2-second time interval.
- the minute ventilation sensing circuit 210 provides a "minute ventilation value" contained in the register at the end of each 2-second time interval, then clears the register.
- the minute ventilation values received during the step 306 are used to determine a first minute ventilation threshold value and a second minute ventilation threshold value.
- the first and second minute ventilation threshold values are used to determine a transition from an "awake” state of the patient to a "sleep" state of the patient.
- the "predetermined period of time" in the step 306 is preferably at least 24 hours, and preferably a multiple of 24 hours, such that: (i) a first portion of the minute ventilation values received during the predetermined period of time are obtained when the patient is awake, (ii) a second portion of the minute ventilation values received during the predetermined period of time are obtained when the patient is asleep, and (iii) a ratio between the first portion and the second portion is representative of a wake-sleep cycle of the patient 108.
- the first minute ventilation threshold value is greater than the second minute ventilation threshold value, and is used to screen the received minute ventilation value to determine if the carrying out of the remaining steps of the recu ⁇ ent portion 304 is wa ⁇ anted.
- a median value of the minute ventilation values received during the predetermined period of time is determined.
- the first minute ventilation threshold value is set to half the median value.
- the median value is substantially the "middle" minute ventilation value. That is, a number of the minute ventilation values received during the predetermined period of time are greater than the median value, and a substantially equal number of the minute ventilation values are less than the median value.
- the CPU 204 (Fig. 2) of the pacemaker 102 may receive minute ventilation values from the minute ventilation sensing circuit 210 (Fig. 2) at 2-second intervals over a 24-hour period of time. Each time the
- the CPU 204 may store the minute ventilation value in the memory 206 (Fig. 2). At the end of the 24-hour period of time, the CPU 204 may access the minute ventilation values stored in the memory 206, determine a median value of the minute ventilation values, and set the first minute ventilation threshold value to half the median value. Alternately, the CPU 204 (Fig. 2) of the pacemaker 102 (Figs. 1-2) may form a histogram of received minute ventilation values within the memory 206 (Fig. 2), and use the histogram to estimate the median value of the minute ventilation values. A range of expected minute ventilation values may be divided into equally-sized sub-ranges or "bins," and different memory locations of the memory 206 may be allocated for each of the bins.
- the CPU 204 may determine which bin the minute ventilation value co ⁇ esponds to, and add ' 1 ' to a running count maintained in the memory location allocated for that bin. At the end of the predetermined period of time (e.g., 24 hours), the CPU 204 may access the memory locations allocated for the bins, locate a bin wherein a number counts in bins above and below the bin are substantially equal, and select the median value within the sub-range of minute ventilation values represented by the bin. The CPU 204 may then set the first minute ventilation threshold value to half the selected median value. Regarding the determining of the second minute ventilation value, the CPU 204 (Fig. 2) of the pacemaker 102 (Figs.
- 1-2 may keep a running estimate of a mean value (i.e., an average value) of the received minute ventilation values.
- the mean value represents a "central tendency" of the received minute ventilation values.
- the CPU 204 may calculate a measure of deviation of the minute ventilation values received during the time interval from a "cu ⁇ ent" estimate of the mean value.
- the CPU 204 may form a histogram of the deviations of the minute ventilation values from the mean value.
- a histogram of deviations of minute ventilation values from a mean value formed over a "sleep-wake" cycle of the patient, has a first peak representing deviations of minute ventilation values from the mean value when the patient is asleep, a second peak representing deviations of minute ventilation values from the mean value when the patient is awake, and a "trough” between the first and second peaks representing deviations of minute ventilation values from the mean value when the patient is transitioning between the "awake” state and the "sleep" state.
- the CPU 204 may select a value for the second minute ventilation threshold value between the first and second peaks of the histogram. For example, the CPU 204 (Fig.
- a standard deviation of minute ventilation values received during predetermined time intervals i.e., time "windows"
- a histogram of resulting minute ventilation standard deviation values within the memory 206 Fig. 2.
- a range of expected minute ventilation standard deviation values may be divided into equally-sized sub-ranges or "bins," and different memory locations of the memory 206 may be allocated for each of the bins.
- the CPU 204 may calculate the minute ventilation standard deviation value, determine which bin the minute ventilation standard deviation value co ⁇ esponds to, and add ' 1 ' to a running count maintained in the memory location allocated for that bin.
- the CPU 204 may access the memory locations allocated for the bins.
- the CPU 204 may locate a bin having a lowest count between two other bins having the highest counts.
- the two bins having the highest counts include a bin of the first peak and a bin of the second peak, and the bin having the lowest count in between the first and second peaks is a bin of the trough of the histogram.
- the CPU 204 may select the second minute ventilation threshold value as a value (e.g., a minimum value) within the sub-range of minute ventilation values represented by the bin having the lowest count.
- the CPU 204 may select the second minute ventilation threshold value as a value (e.g., a minimum value) within a sub-range of minute ventilation values represented by a bin between the bin having the lowest count and the bin of the first peak having one of the two highest count. Further, The CPU 204 may select the second minute ventilation threshold value as a value (e.g., a minimum value) within a sub-range of minute ventilation values represented by a bin midway between the bins of the first and second peaks and having the two highest counts. As described above, at least some of the steps of the recu ⁇ ent portion 304 are carried out at predetermined time intervals. During a step 310 of the recu ⁇ ent portion 304, a minute ventilation value is received during one of the predetermined time intervals. The minute ventilation value is used to calculate an "MV Stdev Short" value and an "MV
- the "MV Stdev Short” value is a standard deviation of minute ventilation values received during m time intervals including the cu ⁇ ent time interval and an immediately preceding m- ⁇ time intervals.
- the “MV Stdev Long” value is a standard deviation of minute ventilation values received during n time intervals including the cu ⁇ ent time interval and the immediately preceding n-l time intervals.
- n ⁇ m; however, for improved perfo ⁇ nance, n is preferably greater than m.
- the value of m may be selected such that the "MV Stdev Short” value is calculated over a 2-5 minute period of time
- the value of n may be selected such that the "MV Stdev Long” value is calculated over a 10-15 minute period of time.
- the minute ventilation sensing circuit 210 may produce a new minute ventilation value at the end of predetermined time intervals (e.g., 2- second time intervals).
- the CPU 204 may keep a running estimates of mean values (i.e., average values) of minute ventilation values received during various predetermined periods of time or time "windows.”
- the CPU 204 may update the running estimates of the mean values each time a new minute ventilation value is produced by the minute ventilation sensing circuit 210 using:
- Mean(i) is the mean value estimate during an zth time interval
- MV(i) is the minute ventilation value produced the minute ventilation sensing circuit 210 during the zth time interval
- p is the total number of elapsed time intervals
- Mean(i- 1 ) is the mean value estimate during the time interval immediately preceding the r ' th time interval.
- the CPU 204 (Fig. 2) of the pacemaker 102 (Figs. 1-2) may receive minute ventilation values at 2-second time intervals, and memory locations of the memoiy 206 (fig. 2) may be allocated for minute ventilation values obtained during the immediately preceding n-l 2-second time intervals.
- the CPU 204 (Fig. 2) of the pacemaker 102 (Figs. 1-2) may receive a "cu ⁇ ent” minute ventilation value, and access the memory locations allocated for the minute ventilation values obtained during the immediately preceding n-l 2-second time intervals.
- the CPU 204 may use the "cu ⁇ ent" minute ventilation value and the minute ventilation values obtained over the immediately preceding m- ⁇ time intervals to compute the "MV Stdev Short" value.
- the CPU 204 may use the "cu ⁇ ent" minute ventilation value and the minute ventilation values obtained over the immediately preceding m- ⁇ time intervals to compute the "MV Stdev Short" value.
- CPU 204 may also use the "cu ⁇ ent” minute ventilation value and the minute ventilation values obtained over the immediately preceding n-l time intervals to compute the "MV Stdev Long” value.
- the "MV Stdev Long” value is compared to the first minute ventilation threshold value determined during the step 308. If the "MV Stdev
- an optional step 316 may be accomplished.
- a step 336 is accomplished.
- an "elapsed time” value is set to zero, and the recu ⁇ ent portion 304 of the method 300 is exited.
- Steps 316-320 represent an optional "activity cross-check" section of the recu ⁇ ent portion 304 of the method 300. Steps 316-320 are believed to enhance performance of the method 300, but need not be accomplished for method 300 to work.
- an "activity value" is received during the predetermined time interval, wherein the activity value is indicative of a degree of movement of the patient during the predetermined time interval.
- the CPU 204 (Fig. 2) of the pacemaker 102 may receive activity values from the activity sensing circuit 212 (Fig. 2) at 2-second intervals.
- the activity sensing circuit 212 may include and accelerometer, a bandpass filter, comparison circuitry, summing circuitry, and a register. An output signal of the accelerometer may be passed through the bandpass filter, and the resultant filtered output signal provided to the comparison circuitry.
- the comparison circuitry may compare the filtered output signal to a threshold value (e.g., a programmable threshold value).
- the summing circuitry may sum the "activity counts” occurring within a 2-second time interval in the register. At the end of each 2-second time interval, the activity sensing circuit 212 may provide the digital sum of the "activity counts" contained in the register, constituting the "activity value," and the register may be cleared.
- the activity value is used to calculate an "ActThreshold” value, wherein the "ActThreshold” value is a sum of all "activity values” obtained during q time intervals including the cu ⁇ ent time interval and an immediately preceding q- time intervals.
- the value of q may be, for example, 20.
- the "ActThreshold" value during a "cu ⁇ ent' time interval k may be expressed as:
- ActThreshold * ⁇ ⁇ MV(k -q -j)
- Step 320 the activity value and the "ActThreshold" value calculated during the step 318 are compared. If the activity value is less than the "ActThreshold” value, an optional step 322 may be accomplished. On the other hand, if the activity value is greater than or equal to the "ActThreshold” value, the step 336 is accomplished. As described above, during the step 336, the "elapsed time” value is set to zero, and the recu ⁇ ent portion 304 of the method 300 is exited. Steps 322-324 represent an optional "time-of-day cross-check" section of the recu ⁇ ent portion 304 of the method 300. Steps 322-324 are believed to enhance performance of the method 300, but need not be accomplished for method 300 to work. I
- a "TimeofDay” value is obtained, wherein the "TimeofDay” value is indicative of a cu ⁇ ent time of day.
- the "TimeofDay” value is compared to a predetermined "ExpectedSleepTime” value, wherein the "ExpectedSleepTime” value is indicative of a time of day the patient is expected to go to sleep each day.
- the "ExpectedSleepTime” value may be, for example, a programmable value. If the "TimeofDay” value is greater than or equal to the "ExpectedSleepTime” value, an optional step 322 may be accomplished.
- the step 336 is accomplished. As described above, during the step 336, the "elapsed time” value is set to zero, and the recu ⁇ ent portion 304 of the method 300 is exited. During a step 326, a length of the predetermined time interval is added to the "Elapsed Time” value. The "Elapsed Time” value is compared to an "ExpectedSleepTransitionTime” value during a decision step 328, wherein the "ExpectedSleepTransitionTime” value is a period of time allotted for the patient to transition from the "awake” state to the "sleep” state.
- the "ExpectedSleepTime” value may be, for example, a programmable value. If the "Elapsed Time” value is greater than or equal to the "ExpectedSleepTransitionTime” value, a decision step 330 is accomplished. On the other hand, if the "Elapsed Time” value is less than the “ExpectedSleepTransitionTime” value, the step 336 is accomplished. As described above, during the step 336, the "elapsed time” value is set to zero, and the recu ⁇ ent portion 304 of the method 300 is exited. During the decision step 330, the "MV Stdev Long” value is compared to the "MV Stdev Short" value.
- MV Stdev Long value is greater than or equal to the "MV Stdev Short” value
- a decision step 332 is accomplished.
- the step 336 is accomplished.
- the decision step 330 enhances the method 300 by detecting abrupt transitions from the "sleep” state to the "awake” state.
- the patient's minute ventilation decreases monotonically over time.
- the "MV Stdev Long” value is typically greater than or equal to the "MV Stdev Short” value.
- the "MV Stdev Short” value will become greater than the "MV Stdev Long” value, indicating the patient has transitioned from the "sleep” state to the "awake” state.
- the "MV Stdev Long” value and the second minute ventilation threshold value, calculated during the step 308, are compared. If the "MV
- a step 334 is accomplished.
- the step 336 is accomplished.
- the "elapsed time” value is set to zero, and the recu ⁇ ent portion 304 of the method 300 is exited.
- the patient is determined to have transitioned from the "awake” state to the "sleep" state.
- Fig. 4 is a flow chart of one embodiment of a method 400 for providing a therapy to a patient (e.g., the patient 108 of Fig. 1).
- the method 400 may be embodied within software residing in the memory 206 (Fig. 2) of the pacemaker 102 (Figs. 1-2).
- the CPU 204 (Fig. 2) may carry out the method 400 when executing the software embodying the method 400.
- a first step 402 of the method 400 an onset of sleep is dete ⁇ nined in the patient.
- the step 402 of the method 400 may be accomplished by carrying out the steps of the method 300 of Figs. 3A-3D.
- the therapy provided to the patient is modified. For example, in the embodiment of Fig.
- the pacemaker 102 includes the pacing output circuitry 202, the CPU 204, and the timing/pacing control circuitry 208.
- the pacing output circuitry 202 produces atrial and ventricular pacing pulses for stimulating the heart 110.
- the CPU 204 may store programmable "demand" mode, "low rate limit,” and "AV interval" values in one or more registers of the timing/pacing control circuitry 208.
- the timing/pacing control circuitry 208 includes sensing circuitry that receives and detects intrinsic electrical signals present within the heart 110 of the patient 108. Specifically, the sensing circuitry of the timing/pacing control circuitry 208 receives a first electrical signal indicative of an intrinsic contraction of the right atrium via the atrial lead
- the sensing circuitry may generate an "atrial beat" signal within the timing/pacing control circuitry 208. If the "demand" mode of the pacemaker 102 is enabled, the timing/pacing control circuitry 208 may provide an "atrial trigger” signal to the pacing output circuitry 202 if a frequency at which the "atrial beat” signals are generated is below the programmed “low rate limit.” In other words, the timing/pacing control circuitry 208 may provide an "atrial trigger” signal to the pacing output circuitry 202 if the intrinsic beat rate of the heart 110 falls below the programmed "low rate limit.” In response to the atrial trigger signal, the pacing output circuitry 202 may produce an atrial pacing pulse, and provide the atrial pacing pulse to the right atrium of the heart 110 via the atrial lead 104.
- the CPU 204 may embody the above described method 300 for detecting onsets of sleep in the patient 108, and/or the method 400 for providing a therapy to a patient. For example, having detected an onset of sleep in the patient 108 (e.g., during the step 334 of the method 300), the CPU 204 may reduce the "low rate limit" value stored in the timing/pacing control circuitry 208 from a normal "resting rate” value (e.g., 60 beats per minute) to a "sleep rate” value, wherein the "sleep rate” value is less than or equal to the "resting rate.”
- the "sleep rate" value may be, for example, a programmable value.
- “sleep rate” value may be, for example, between 50 beats per minute and 60 beats per minute.
- the above described methods 300 and 400 may also be useful for other purposes than reducing "low rate limit" values from normal “resting rate” values to "sleep rate” values in pacemakers.
- the method 300 may be used to detect onsets of sleep for monitoring sleep-related events (i.e. sleep apnea, etc.), and the method 400 may be used in providing other medical therapies (e.g., electrical shocks for treating atrial fibrillation, administration of medications, etc.).
- Figs. 5 A and 5B will now be used to further describe the calculation of the second minute ventilation threshold value. Fig.
- minute ventilation sensing circuitry is a histogram of minute ventilation values of a patient obtained via minute ventilation sensing circuitry over a 24-hour period.
- minute ventilation sensing circuitry delivered cu ⁇ ent pulses at a rate of 16 Hz, thereby defining pulse "cycles" having "cycle times" of 1/16 or 0.0625 seconds.
- the minute ventilation sensing circuitry converted an analog difference voltage between a "cu ⁇ ent” value of a thoracic impedance signal, obtained during a "cu ⁇ ent” pulse cycle, and a "previous" value of the thoracic impedance signal, obtained during a pulse cycle immediately preceding the cu ⁇ ent pulse cycle, to a digital "count" value.
- the minute ventilation sensing circuitry summed 32 of the digital "count” values produced by the analog-to-digital conversion circuitry in a register over predefined 2-second time intervals. At the end of each 2-second time interval, the minute ventilation sensing circuitry produced a "minute ventilation value" contained in the register, and the register is cleared. A range of expected minute ventilation values was divided into equally-sized subranges or "bins," and different memory locations of a memory were allocated for each of the bins. Each time a minute ventilation value was produced by the minute ventilation sensing circuitry, a determination was made as to which bin the minute ventilation value co ⁇ esponds to, and a ' 1' was added to a running count maintained in the memory location allocated for that bin.
- Fig. 5B is a histogram of standard deviations of the minute ventilation values used to form the histogram of Fig. 5A and received within 1 -minute time windows.
- the minute ventilation sensing circuitry produced a new minute ventilation value at the end of each 2-second time interval.
- a running estimate of a mean of the minute ventilation values was updated each time a new minute ventilation value was produced by the minute ventilation sensing circuitry as described above.
- the histogram of Fig. 5B was formed within a memory. A range of expected minute ventilation standard deviation values was divided into equally-sized sub-ranges or "bins," and different memory locations of the memory were allocated for each of the bins. At the end of each 1 -minute time window, the co ⁇ esponding minute ventilation standard deviation value was calculated. A determination was made as to which bin the minute ventilation standard deviation value co ⁇ esponded to, and ' 1 ' was added to a miming count maintained in the memory location allocated for that bin. At the end of the 24-hour time period, the contents of the memory locations allocated for the bins were read out.
- the histogram of Fig. 5B has a first peak 500, a second peak 502, and "trough"
- the second minute ventilation threshold value may be selected from among the minute ventilation values located in the trough 504.
- the second minute ventilation threshold value may be selected as a value (e.g., a minimum value) within the sub-range of minute ventilation values represented by the bin having the lowest count (i.e., a bin having the lowest count within the trough 504.).
- the second minute ventilation threshold value may be selected as a value (e.g., a minimum value) within a sub-range of minute ventilation values represented by a bin between the bin having the lowest count within the trough 504 and a bin of the first peak 500 having the highest count. Further, the second minute ventilation threshold value may be selected as a value (e.g., a minimum value) within a sub-range of minute ventilation values represented by a bin midway between a bin of the first peak 500 having a highest count, and a bin of the second peak 502 having a highest count. Fig.
- FIG. 6 is a graph of "MV Stdev Long” and "MV Stdev Short” values described above, wherein the "MV Stdev Long” and “MV Stdev Short” values were calculated using minute ventilation values produced during 2-second time intervals and indicative of the minute ventilation of a patient.
- the first minute ventilation threshold value described above defines an "MV Threshold 1" level
- the second minute ventilation threshold value described above defines an "MV Threshold 2" level.
- the “MV Threshold 1" level is greater than the "MV Threshold 2" level.
- the first minute ventilation threshold value is used to screen a received minute ventilation value to determine if the received minute ventilation value is sufficiently low as to wa ⁇ ant further analysis to detect an onset of sleep.
- a time of day labeled "Sleep Onset" in Fig. 6 is a time the method 300 of Figs. 3 A-3D determine an onset of sleep in the patient. Prior to the "Sleep Onset" time, the
- MV Stdev Short” and “MV Stdev Long” values drop below the "MV Threshold 1" level several times, and occasionally drop below the "MV Threshold 2" level, indicating a decrease in patient activity and an impending transition from an "awake” state to a "sleep” state.
- the "MV Stdev Long” value drops below the "MV Threshold 1" level, thus indicating received minute ventilation values are sufficiently low as to wa ⁇ ant further analysis to detect an onset of sleep. (See the step 314 of the method 300, Fig. 3 A.)
- Fig. 7 is a graph of "MV Stdev Long” values described above, wherein the "MV Stdev Long” values were calculated using minute ventilation values produced during 2- second time intervals and indicative of the minute ventilation of a patient. As in Fig.
- the first minute ventilation threshold value described above defines a level labeled "MV Threshold 1”
- the second minute ventilation threshold value described above defines a level labeled "MV Threshold 2.”
- a time of day labeled "Sleep Onset” in Fig. 7 is a time the method 300 of Figs. 3 A-3D determine an onset of sleep in the patient. Prior to the "Sleep Onset” time, the "MV Stdev Long” value substantially remains above the "MV Threshold 1" and “MV Threshold 2" levels, indicating a relatively high level of patient activity characteristic of an "awake” state of the patient.
- the "MV Stdev Long” value drops below the "MV Threshold 1" level several times, and occasionally drops below the “MV Threshold 2" level, indicating a decrease in patient activity and an impending transition from the "awake” state to a "sleep” state.
- the "MV Stdev Long” value has dropped below the "MV Threshold 2" level for a period of time equal to the "ExpectedSleepTransitionTime” described above. (See the step 328 of the method 300, Fig. 3D.) The patient woke up at a time of day labeled "Patient Wakes Up” in Fig. 7.
- FIG. 7 is an illustration of an alternative embodiment of an implantable medical device system including an implantable cardioverter defibrillator, refe ⁇ ed to hereafter as
- ICD implanted to a patient's heart by way of three leads 6, 15, and 16.
- a connector block 12 receives the proximal end of a right ventricular lead 16, a right atrial lead 15 and a coronary sinus lead 6, used for positioning electrodes for sensing and stimulation in three or four heart chambers.
- the right ventricular lead 16 is positioned such that its distal end is in the right ventricle (RV) for sensing right ventricular cardiac signals and delivering pacing or shocking pulses in the right ventricle.
- RV right ventricle
- right ventricular lead 16 is equipped with a ring electrode 24, a tip electrode 26, optionally mounted retractably within an electrode head 28, and RV coil electrode 20, each of which are connected to an insulated conductor contained within the body of lead 16.
- the proximal end of the insulated conductors are coupled to co ⁇ esponding connectors ca ⁇ ied by a connector 14 at the proximal end of lead 16 for providing electrical connection to the ICD 10.
- the right atrial lead 15 is positioned such that its distal end is in the vicinity of the right atrium and the superior vena cava (SVC).
- Lead 15 is equipped with a ring electrode 21 and a tip electrode 17, optionally mounted retractably within electrode head 19, for sensing and pacing in the right atrium.
- Lead 15 is further equipped with an SVC coil electrode 23 for delivering high-energy shock therapy.
- the ring electrode 21, the helix electrode 17 and the SVC coil electrode 23 are each connected to an insulated conductor with the body of the right atrial lead 15.
- Each insulated conductor is coupled at its proximal end to a connector terminal carried by connector 13.
- the coronary sinus lead 6 is advanced within the vasculature of the left side of the heart via the coronary sinus and great cardiac vein.
- the coronary sinus lead 6 is shown in the embodiment of Figure 8 as having a defibrillation coil electrode 8 that may be used in combination with either the RV coil electrode 20 or the SVC coil electrode 23 for delivering electrical shocks for cardioversion and defibrillation therapies.
- coronary sinus lead 6 may also be equipped with a distal tip electrode and ring electrode for pacing and sensing functions in the left chambers of the heart.
- the coil electrode 8 is coupled to an insulated conductor within the body of lead 6, which provides connection to the proximal connector 4.
- the electrodes 17 and 21 or 24 and 26 may be used as bipolar pairs, commonly refe ⁇ ed to as a "tip-to-ring" configuration, or individually in a unipolar configuration with the device housing 11 serving as the indifferent electrode, commonly refe ⁇ ed to as the "can" or "case” electrode.
- the device housing 11 may also serve as a subcutaneous defibrillation electrode in combination with one or more of the defibrillation coil electrodes 8, 20 or 23 for defibrillation of the atria or ventricles. It is recognized that alternate lead systems may be substituted for the three lead system illustrated in Figure 8.
- FIG. 8 is a diagram of one embodiment of the ICD of Figure 8.
- ICD 10 produces
- the ICD 10 includes lead interface circuitry 200, pacing output circuitry 202, a central processing unit (CPU) 204, a memory 206, timing/pacing control circuitry 208, a MV sensing circuit 210, an activity sensing circuitry 212, a telemetry unit 214, and an antenna 216, all of which may co ⁇ espond generally to the identically-labeled components included in pacemaker 102 described above in conjunction with Figure 9.
- ICD 10 additionally includes cardioversion/defibrillation output unit 218 for delivering high- voltage shock pulses.
- the lead interface circuitry 200 is adapted for receiving the high-voltage right atrial lead 15, high- voltage right ventricular lead 16, and high- voltage coronary sinus lead 6.
- the electrodes ca ⁇ ied by the leads 15, 16, and 6 may be selected via lead interface circuitry 200 for the various sensing, pacing, and cardioversion/defibrillation functions of ICD 10.
- the timing/pacing control circuitry 208 includes sensing circuitry that receives and detects intrinsic electrical signals from sensing electrodes included on right atrial lead 15 and right ventricular lead 16.
- Timing/pacing control circuitry 208 includes various registers for storing values indicative of programmed parameters of the ICD 10, and various counters for performing timing functions.
- timing/pacing control circuitry 208 the durations of escape intervals used in controlling the timing of pacing pulses delivered by ICD 10 are stored by timing/pacing control circuitry 208.
- the value of a count present in an escape. interval counter when reset by sensed R-waves or P-waves can be used to measure R-R intervals, P-P intervals, P-R intervals, and R-P intervals, which measures are stored in memory 206 and used to diagnose the occu ⁇ ence of a variety of a ⁇ hythmias by CPU 204.
- Timing/pacing and control 208 may further include an analog-to-digital converter to digitize electrical signals received from the heart from sensing electrodes on leads 15 and 16.
- CPU 204 may employ digital signal analysis techniques to characterize the digitized signals received from timing pacing/control 208 and stored in memoiy 206 to recognize and classify the patient's heart rhythm employing any of the numerous signal processing methods known in the art.
- an anti-tachycardia pacing therapy may be delivered to the patient's heart by loading a regimen from CPU 204 into the pacer timing/control circuitry 208 according to the type of tachycardia detected.
- CPU 204 activates the cardioversion/defibrillation output unit 218 to initiate charging of high voltage capacitors via a charging circuit included therein. Timing of the delivery of the defibrillation or cardioversion shock pulse is controlled by pacer timing/control circuitry 208. In accordance with the present invention, activation of cardioversion/defibrillation output unit 218 by CPU 204 may be delayed or cancelled pending the detection of sleep according to minute ventilation values provided by MV sensing circuit 210 to CPU 204 as described above. In modern ICDs, the particular a ⁇ hythmia therapies are programmed into the device ahead of time by the physician, and a menu of therapies is typically provided.
- the menu of therapies is often refe ⁇ ed to as "tiered" therapies in that the therapies tend to progress from relatively lower-energy, less aggressive therapies, to higher-energy, more aggressive therapies.
- an anti-tachycardia pacing therapy may be selected on initial detection of tachycardia.
- a more aggressive anti-tachycardia pacing therapy may be scheduled.
- a higher-level cardioversion shock pulse therapy may be selected thereafter.
- the amplitude of a cardioversion/defibrillation shock may be incremented in response to failure of an initial shock or shocks to terminate tachycardia/fibrillation.
- a tiered therapy sequence may be initiated by CPU 204 in response to a detected atrial a ⁇ hythmia.
- the therapy sequence may proceed up to a programmed high- voltage shock therapy.
- a programmed shock therapy may be postponed until a predetermined time after sleep onset is detected by CPU 204 according to the method 300 of Figures 3 A through 3D.
- the programmed shock therapy may be delivered without delay.
- FIG. 10 is a flow chart summarizing the steps performed in one embodiment of a method for controlling the delivery of high-energy shock pulses for treating atrial a ⁇ hythmias pending the detection of sleep.
- Method 800 is initiated at step 802 upon detection of AT or AF.
- a determination is made whether sleep onset was detected within a predete ⁇ nined interval of time prior to the AT/AF detection.
- Sleep onset is preferably detected based on the deviation of MV values from a MV statistical parameter as described previously in conjunction with Figures 3A through 3D.
- sleep onset may also be detected using other known detection schemes, such as described, for example, in U.S. Patent No. 6,128,534 issued to Park et al., U.S. Patent No. 5,814,087 issued to Renrie, and U.S. Patent No. 5,476,483 issued to Bornzin et al., all of which are incorporated herein by reference in their entireties.
- CV/DF programmed cardioversion/defibrillation
- a programmed CV/DF shock is cancelled at step 808. It is to be understood that other a ⁇ hythmia therapies programmed to be delivered in a menu of therapies may be delivered upon detection of AT/AF at step 802. If a high-energy cardioversion or defibrillation shock is included in the menu of therapies, however, prior to preparing for shock delivery, i.e., prior to initiating capacitor charging, a verification that sleep onset was previously detected is made (step 804). The sleep onset detection is preferably made within a predetermined window of time, for example within the last 15 to 30 minutes, such that the patient is still expected to be asleep.
- Figure 11 is a flow chart summarizing the steps performed in an alternative embodiment of a method for controlling the delivery of high-energy shock pulses for treating atrial a ⁇ hythmias pending the detection of sleep.
- a programmed shock therapy may be delayed until a time after sleep onset is detected.
- Method 900 begins at step 902 upon AT/AF detection, after which monitoring for the onset of sleep is performed at step 904. Sleep onset is detected based on long-term and relatively shorter-term MV parameter evaluation as described previously. If sleep onset is detected, as determined at decision step 906, method 900 proceeds to step 910 to monitor for arousal.
- method 900 continues monitoring for sleep onset by returning to step 904.
- MV parameter values are determined at the end of each MV sensor time interval, e.g., at the end of 2 seconds.
- a comparative analysis of the MV parameter values e.g., "MV Stdev Long” and "MV Stdev Short” as described previously, for determining if the onset of sleep has occu ⁇ ed.
- Monitoring for arousal at step 910 involves a similar process in that at the end of each MV sensor time interval, MV parameter values are determined.
- These MV parameter values are evaluated in a comparative analysis at step 912 to determine if sleep is no longer indicated, z ' .e., arousal has occu ⁇ ed.
- the "MV Stdev Long” value is typically greater than or equal to the "MV Stdev Short” value.
- the "MV Stdev Long" value is typically greater than or equal to the "MV Stdev Short” value.
- the "MV Stdev Long” value is typically greater than
- Stdev Short value will become greater than the "MV Stdev Long” value, indicating the patient has transitioned from the "sleep” state to the "awake” state.
- arousal may be detected at step 912 based on a "MV Stdev Short value” becoming greater than the "MV Stdev Long” value subsequent to the sleep onset detection. If arousal is detected, method 900 returns to step 904 to resume monitoring for sleep onset. Any elapsed time measured since the onset of sleep detection is reset to zero at step 914. If arousal is not detected at decision step 912, the elapsed time since sleep onset detection is measured at step 916.
- the MV sensor time interval e.g., 2 seconds
- the MV sensor time interval is added to the "cu ⁇ ent" elapsed time value at step 916.
- the elapsed time is compared to a "shock wait time.”
- the "shock wait time” is a predetermined, programmable amount of time after which a delayed CV/DF shock will be delivered.
- the "shock wait time” preferably co ⁇ esponds to the time no ⁇ nally required for a patient to reach a deep sleep stage after sleep onset. Typically, a person enters deep sleep approximately 20 minutes after sleep onset occurs if not aroused or disturbed.
- a “shock wait time” may appropriately be set, therefore, between 20 and 60 minutes, for example.
- the ICD 10 may verify that the AT/AF is still being detected at decision step 920 and, if so, deliver the delayed CV/DF shock thereafter at step 922. If the elapsed time since sleep onset detection has not reached the "shock wait time," the patient is presumably not yet in a deep sleep stage. Method 900 returns to step 910 to continue monitoring for arousal and measuring the elapsed time since sleep onset if arousal is not detected. If AT/AF is no longer being detected after the elapsed time equals the "shock wait time", as determined at decision step 918, delivery of the delayed shock is no longer appropriate.
- Method 900 is then terminated at step 924, and the delayed shock is canceled.
- Figure 12 is a flow chart providing additional details included in one embodiment of the step for detecting arousal included in method 900 of Figure 11. Steps for monitoring for arousal that may be included in step 910 of method 900 are grouped within dashed line in Figure 12. After detecting sleep onset at step 906 of method 900 ( Figure 11) as described previously, monitoring for arousal commences at step 926 wherein computational circuitry receives the next MV value determined during a predete ⁇ nined time interval, e.g., 2 seconds, from MN sensing circuitry.
- a predete ⁇ nined time interval e.g. 2 seconds
- the received MV value is used to calculate a cu ⁇ ent "MV Stdev Short” value and a cu ⁇ ent "MV Stdev Long” value as indicated at step 928 and as described previously.
- the cu ⁇ ent "MV Stdev Short” value is compared to the cu ⁇ ent "MV Stdev Long” value. If the "MV Stdev
- MV Stdev Short value has become greater than the "MV Stdev Long” value, the patient may have become active indicating arousal. If the cu ⁇ ent "MV Stdev Short” value has also exceeded the second "MV threshold” value described previously, arousal is detected at step 934. On the other hand, if the "MV Stdev Short” value is not greater than the “MV Stdev Long” value (step 930), or if the "MV Stdev Short” value is greater than the "MV Stdev Long” value but is still less- than the second "MV Threshold” value (step 932), a "sleep" state detection is sustained as indicated at step 936.
- FIG. 13 is a flow chart summarizing the steps performed in yet another embodiment of a method for controlling the delivery of high-energy shock pulses for treating atrial a ⁇ hythmias pending the detection of sleep. Steps 902 through 924 included in method 950 shown in Figure 13 co ⁇ espond to identically-labeled steps included in method 900 of Figure 11, described above.
- a pending shock therapy may be withheld indefinitely if the programmed "shock wait time" is never reached (at step 918) after a sleep onset detection is made (step 906).
- the "shock wait time” may not be reached during a period of sleep, for example, when a patient is restless or experiences frequent arousals during the night. Thus, a pending shock therapy will not be delivered. It may be undesirable, however, to withhold a pending AT/AF shock therapy for an extended period of time, for example for more than 24 to 48 hours.
- a pending shock therapy may be scheduled to occur at a particular time of day, e.g., 4 a.m., or after a shortened "shock wait time," whichever occurs first.
- method 950 of Figure 13 includes additional steps for ensuring that a pending shock therapy is not withheld indefinitely. If arousal is detected at step 912 of Figure 13, after a sleep onset detection is made at step 906, an elapsed time counter is reset at step 914 as described previously. However, before returning to step 904 to monitor for sleep onset again, method 950 determines if a "maximum pending shock time" has expired at step 940. If not, method 950 proceeds to step 904.
- a “maximum pending shock time” may be defined as an interval of time measured from the time of AT/AF detection.
- a maximum pending shock time may be programmed as a number of minutes or hours following an AT/AF detection, e.g., 12, 18 or 24 hours.
- a “maximum pending shock time” may be programmed to co ⁇ espond to a time of day.
- the maximum pending shock time may expire at a scheduled time of day, such as 7:00 a.m., indicating the end of "night time.” If the "shock wait time” is not reached during the first night following AT/AF detection, the "maximum pending shock time” will be reached. Upon reaching the "maximum pending shock time,” at step 940 the "shock wait time” is shortened at step 942. After the "shock wait time” is shortened, method 950 continues to step 904 to monitor for the onset of sleep. If the elapsed time measured following a sleep detection (step 916) reaches the shortened "shock wait time" (step 918), and AT/AF is still being detected (step 920), the shock therapy is delivered at step 922.
- a scheduled time of day such as 7:00 a.m.
- a shock therapy may be delivered at a scheduled, "default” shock delivery time.
- method 950 determines if the "maximum pending shock time" has been exceeded and a scheduled "default” shock delivery time has been reached at decision step 944. If these conditions are satisfied, the shock therapy is delivered at step 922 after verifying the sustained AT/AF detection at step 920.
- a "default" shock delivery time may be programmed to a time of day, for example 4:00 a.m., at which the patient is expected to be resting.
- method 950 returns to step 910 to continue to monitor for arousal.
- the pending shock therapy will thus be delivered, at step 922: after the originally programmed "shock wait time” following a sleep onset detection; after a shortened “shock wait time” if a "maximum pending shock time” has expired; or at a scheduled “default” shock delivery time if a "maximum pending shock time” has expired, which ever occurs first.
- the programmable processor may include one or more individual processors, which may act independently or in concert.
- a "computer-readable medium” includes but is not limited to any type of computer memory such as floppy disks, conventional hard disks, CR-ROMS, Flash ROMS, nonvolatile ROMS, RAM and a magnetic or optical storage medium.
- the medium may include instructions for causing a processor to perform any of the features described above for initiating a session of the escape rate variation according to the present invention.
- the particular embodiments disclosed above are illustrative only, as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein.
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
- Steroid Compounds (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/736,370 US7206635B2 (en) | 2001-06-07 | 2003-12-15 | Method and apparatus for modifying delivery of a therapy in response to onset of sleep |
PCT/US2004/040359 WO2005061046A2 (en) | 2003-12-15 | 2004-12-01 | Method and apparatus for modifying delivery of a therapy in response to onset of sleep |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1706174A2 true EP1706174A2 (en) | 2006-10-04 |
EP1706174B1 EP1706174B1 (en) | 2009-04-22 |
Family
ID=34710465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04812801A Not-in-force EP1706174B1 (en) | 2003-12-15 | 2004-12-01 | Apparatus for modifying delivery of a therapy in response to onset of sleep |
Country Status (7)
Country | Link |
---|---|
US (1) | US7206635B2 (en) |
EP (1) | EP1706174B1 (en) |
CN (1) | CN100563557C (en) |
AT (1) | ATE429266T1 (en) |
CA (1) | CA2549489C (en) |
DE (1) | DE602004020804D1 (en) |
WO (1) | WO2005061046A2 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252640B2 (en) * | 2002-12-04 | 2007-08-07 | Cardiac Pacemakers, Inc. | Detection of disordered breathing |
US7189204B2 (en) | 2002-12-04 | 2007-03-13 | Cardiac Pacemakers, Inc. | Sleep detection using an adjustable threshold |
US7887493B2 (en) | 2003-09-18 | 2011-02-15 | Cardiac Pacemakers, Inc. | Implantable device employing movement sensing for detecting sleep-related disorders |
US7668591B2 (en) * | 2003-09-18 | 2010-02-23 | Cardiac Pacemakers, Inc. | Automatic activation of medical processes |
US8606356B2 (en) * | 2003-09-18 | 2013-12-10 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
US7720541B2 (en) * | 2003-08-18 | 2010-05-18 | Cardiac Pacemakers, Inc. | Adaptive therapy for disordered breathing |
EP1670547B1 (en) | 2003-08-18 | 2008-11-12 | Cardiac Pacemakers, Inc. | Patient monitoring system |
US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
US7967756B2 (en) | 2003-09-18 | 2011-06-28 | Cardiac Pacemakers, Inc. | Respiratory therapy control based on cardiac cycle |
US7591265B2 (en) | 2003-09-18 | 2009-09-22 | Cardiac Pacemakers, Inc. | Coordinated use of respiratory and cardiac therapies for sleep disordered breathing |
US7662101B2 (en) | 2003-09-18 | 2010-02-16 | Cardiac Pacemakers, Inc. | Therapy control based on cardiopulmonary status |
US7510531B2 (en) * | 2003-09-18 | 2009-03-31 | Cardiac Pacemakers, Inc. | System and method for discrimination of central and obstructive disordered breathing events |
US7396333B2 (en) | 2003-08-18 | 2008-07-08 | Cardiac Pacemakers, Inc. | Prediction of disordered breathing |
US8192376B2 (en) | 2003-08-18 | 2012-06-05 | Cardiac Pacemakers, Inc. | Sleep state classification |
US7336996B2 (en) * | 2003-09-18 | 2008-02-26 | Cardiac Pacemakers, Inc. | Rate regularization of cardiac pacing for disordered breathing therapy |
US20050142070A1 (en) * | 2003-09-18 | 2005-06-30 | Hartley Jesse W. | Methods and systems for assessing pulmonary disease with drug therapy control |
US7757690B2 (en) | 2003-09-18 | 2010-07-20 | Cardiac Pacemakers, Inc. | System and method for moderating a therapy delivered during sleep using physiologic data acquired during non-sleep |
US8467876B2 (en) | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
US9259573B2 (en) | 2003-10-15 | 2016-02-16 | Rmx, Llc | Device and method for manipulating exhalation |
US8160711B2 (en) | 2003-10-15 | 2012-04-17 | Rmx, Llc | Multimode device and method for controlling breathing |
US8265759B2 (en) | 2003-10-15 | 2012-09-11 | Rmx, Llc | Device and method for treating disorders of the cardiovascular system or heart |
US8140164B2 (en) | 2003-10-15 | 2012-03-20 | Rmx, Llc | Therapeutic diaphragm stimulation device and method |
US7979128B2 (en) | 2003-10-15 | 2011-07-12 | Rmx, Llc | Device and method for gradually controlling breathing |
US20060167523A1 (en) * | 2003-10-15 | 2006-07-27 | Tehrani Amir J | Device and method for improving upper airway functionality |
US7970475B2 (en) | 2003-10-15 | 2011-06-28 | Rmx, Llc | Device and method for biasing lung volume |
US8244358B2 (en) * | 2003-10-15 | 2012-08-14 | Rmx, Llc | Device and method for treating obstructive sleep apnea |
TWI250326B (en) * | 2003-11-28 | 2006-03-01 | Prime Optical Fiber Corp | Optical fiber inclinometer |
US7747323B2 (en) | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
US7996072B2 (en) | 2004-12-21 | 2011-08-09 | Cardiac Pacemakers, Inc. | Positionally adaptable implantable cardiac device |
US7680534B2 (en) | 2005-02-28 | 2010-03-16 | Cardiac Pacemakers, Inc. | Implantable cardiac device with dyspnea measurement |
FR2891152A1 (en) * | 2005-09-27 | 2007-03-30 | Ela Medical Soc Par Actions Si | ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR DEVICE FOR STIMULATION, RESYNCHRONIZATION, DEFIBRILLATION AND / OR CARDIOVERSION, COMPRISING PREDICTIVE DIAGNOSTIC MEANS FOR THE STATUS OF THE PATIENT |
US20070118180A1 (en) | 2005-11-18 | 2007-05-24 | Quan Ni | Cardiac resynchronization therapy for improved hemodynamics based on disordered breathing detection |
CA2641821C (en) | 2006-02-16 | 2017-10-10 | Imthera Medical, Inc. | An rfid-based apparatus, system, and method for therapeutic treatment of a patient |
US7751887B1 (en) * | 2006-04-28 | 2010-07-06 | Pacesetter, Inc. | Tiered antitachycardia pacing and pre-pulsing therapy |
US8280513B2 (en) | 2006-12-22 | 2012-10-02 | Rmx, Llc | Device and method to treat flow limitations |
US8380314B2 (en) | 2007-09-26 | 2013-02-19 | Medtronic, Inc. | Patient directed therapy control |
EP2207590A1 (en) | 2007-09-26 | 2010-07-21 | Medtronic, INC. | Therapy program selection |
US20090264789A1 (en) * | 2007-09-26 | 2009-10-22 | Medtronic, Inc. | Therapy program selection |
CA2697822A1 (en) | 2007-10-09 | 2009-04-16 | Imthera Medical, Inc. | Apparatus, system, and method for selective stimulation |
WO2009051638A1 (en) | 2007-10-16 | 2009-04-23 | Medtronic, Inc. | Therapy control based on a patient movement state |
EP2249908B1 (en) | 2008-01-25 | 2014-01-01 | Medtronic, Inc. | Sleep stage detection |
US8282580B2 (en) | 2008-07-11 | 2012-10-09 | Medtronic, Inc. | Data rejection for posture state analysis |
BRPI0920548B8 (en) | 2008-10-09 | 2021-06-22 | Imthera Medical Inc | device to control the position of a patient's tongue |
EP3184045B1 (en) | 2008-11-19 | 2023-12-06 | Inspire Medical Systems, Inc. | System treating sleep disordered breathing |
EP2498868A4 (en) | 2009-11-10 | 2013-05-08 | Imthera Medical Inc | System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue |
US9770204B2 (en) * | 2009-11-11 | 2017-09-26 | Medtronic, Inc. | Deep brain stimulation for sleep and movement disorders |
US9211411B2 (en) | 2010-08-26 | 2015-12-15 | Medtronic, Inc. | Therapy for rapid eye movement behavior disorder (RBD) |
CN102266615B (en) * | 2010-12-31 | 2014-08-06 | 北京谊安医疗系统股份有限公司 | Method and device for calculating minute ventilation of medical breathing equipment |
US8509902B2 (en) | 2011-07-28 | 2013-08-13 | Medtronic, Inc. | Medical device to provide breathing therapy |
US9861817B2 (en) | 2011-07-28 | 2018-01-09 | Medtronic, Inc. | Medical device to provide breathing therapy |
JP6092212B2 (en) | 2011-08-11 | 2017-03-08 | インスパイア・メディカル・システムズ・インコーポレイテッドInspire Medical Systems, Inc. | System for selecting a stimulation protocol based on detection results of respiratory effort |
JP6202485B2 (en) * | 2013-01-11 | 2017-09-27 | 株式会社タニタ | Biological information management module, sleep meter, and system |
WO2016033245A1 (en) | 2014-08-26 | 2016-03-03 | Rmx, Llc | Devices and methods for reducing intrathoracic pressure |
AU2016233377B2 (en) | 2015-03-19 | 2020-04-30 | Inspire Medical Systems, Inc. | Stimulation for treating sleep disordered breathing |
US11266838B1 (en) | 2019-06-21 | 2022-03-08 | Rmx, Llc | Airway diagnostics utilizing phrenic nerve stimulation device and method |
CN112754492A (en) * | 2021-01-14 | 2021-05-07 | 苏州无双医疗设备有限公司 | Implantable medical device and programmer for heart rhythm monitoring and anticoagulation |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2415385A1 (en) | 1974-03-29 | 1975-10-02 | Siemens Ag | PACEMAKER |
CA1219040A (en) | 1983-05-05 | 1987-03-10 | Elliot V. Plotkin | Measurement of enzyme-catalysed reactions |
US4702253A (en) * | 1985-10-15 | 1987-10-27 | Telectronics N.V. | Metabolic-demand pacemaker and method of using the same to determine minute volume |
US4795542A (en) | 1986-04-24 | 1989-01-03 | St. Jude Medical, Inc. | Electrochemical concentration detector device |
JPH0341926A (en) * | 1989-07-07 | 1991-02-22 | Matsushita Electric Works Ltd | Detector for change in sleeping state and sleeping state controller |
US5476483A (en) * | 1994-06-10 | 1995-12-19 | Pacesetter, Inc. | System and method for modulating the base rate during sleep for a rate-responsive cardiac pacemaker |
US5562711A (en) | 1994-11-30 | 1996-10-08 | Medtronic, Inc. | Method and apparatus for rate-responsive cardiac pacing |
US5630834A (en) * | 1995-05-03 | 1997-05-20 | Medtronic, Inc. | Atrial defibrillator with means for delivering therapy in response to a determination that the patient is likely asleep |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US5891176A (en) | 1996-05-09 | 1999-04-06 | Pacesetter, Inc. | System and method for providing hemodynamically optimal pacing |
US5814087A (en) | 1996-12-18 | 1998-09-29 | Medtronic, Inc. | Rate responsive pacemaker adapted to adjust lower rate limit according to monitored patient blood temperature |
US5733312A (en) | 1997-01-17 | 1998-03-31 | Pacesetter, Inc. | System and method for modulating the output of an implantable medical device in response to circadian variations |
US5964788A (en) | 1997-10-28 | 1999-10-12 | Pacesetter, Inc. | Method and apparatus for controlling a pacemaker using respiration |
US6128534A (en) | 1998-06-16 | 2000-10-03 | Pacesetter, Inc. | Implantable cardiac stimulation device and method for varying pacing parameters to mimic circadian cycles |
US6055454A (en) | 1998-07-27 | 2000-04-25 | Cardiac Pacemakers, Inc. | Cardiac pacemaker with automatic response optimization of a physiologic sensor based on a second sensor |
US6049735A (en) | 1999-03-01 | 2000-04-11 | Cardiac Pacemakers Inc. | Cardiac rhythm management device with detection and therapy for sudden syncopal events |
US6188927B1 (en) | 1999-04-16 | 2001-02-13 | Pacesetter, Inc. | Implantable cardiac stimulation system having improved method of calibrating physiologic sensors |
US6275733B1 (en) | 1999-06-16 | 2001-08-14 | Pacesetter, Inc. | Dual sensor rate response pacemaker |
US6731984B2 (en) | 2001-06-07 | 2004-05-04 | Medtronic, Inc. | Method for providing a therapy to a patient involving modifying the therapy after detecting an onset of sleep in the patient, and implantable medical device embodying same |
FR2833177B1 (en) | 2001-12-07 | 2004-06-04 | Ela Medical Sa | ACTIVE MEDICAL DEVICE INCLUDING ADVANCED MEANS OF DISCRIMINATION IN THE WAKING AND SLEEPING PHASES |
US6775571B1 (en) | 2001-12-12 | 2004-08-10 | Pacesetter, Inc. | Dynamic control of overdrive pacing based on degree of randomness within heart rate |
US6970743B2 (en) * | 2002-08-30 | 2005-11-29 | Pacesetter, Inc. | System and method for treating abnormal ventricular activation-recovery time |
US8467876B2 (en) * | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
-
2003
- 2003-12-15 US US10/736,370 patent/US7206635B2/en not_active Expired - Lifetime
-
2004
- 2004-12-01 WO PCT/US2004/040359 patent/WO2005061046A2/en active Application Filing
- 2004-12-01 DE DE602004020804T patent/DE602004020804D1/en active Active
- 2004-12-01 CA CA2549489A patent/CA2549489C/en not_active Expired - Fee Related
- 2004-12-01 AT AT04812801T patent/ATE429266T1/en not_active IP Right Cessation
- 2004-12-01 EP EP04812801A patent/EP1706174B1/en not_active Not-in-force
- 2004-12-01 CN CNB2004800405445A patent/CN100563557C/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO2005061046A2 * |
Also Published As
Publication number | Publication date |
---|---|
DE602004020804D1 (en) | 2009-06-04 |
US20040176809A1 (en) | 2004-09-09 |
WO2005061046A2 (en) | 2005-07-07 |
ATE429266T1 (en) | 2009-05-15 |
CN100563557C (en) | 2009-12-02 |
CA2549489A1 (en) | 2005-07-07 |
WO2005061046A3 (en) | 2007-05-24 |
EP1706174B1 (en) | 2009-04-22 |
US7206635B2 (en) | 2007-04-17 |
CA2549489C (en) | 2013-11-19 |
CN101076283A (en) | 2007-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7206635B2 (en) | Method and apparatus for modifying delivery of a therapy in response to onset of sleep | |
EP2213227B1 (en) | Method for monitoring tissue fluid content for use in an implantable cardiac device | |
EP1395336B1 (en) | System for providing therapy and modifying the therapy after detecting an onset of sleep in patient | |
EP1437159B1 (en) | System for detecting circadian states using an implantable medical device | |
JP4477638B2 (en) | Use of accelerometer signals to enhance ventricular arrhythmia detection | |
JP4343107B2 (en) | Method and apparatus for preventing continuously occurring arrhythmia using overdrive pacing | |
US8725258B2 (en) | Method and apparatus for automated adjustment of arrhythmia detection duration | |
JP2005529690A5 (en) | ||
EP1551504A1 (en) | Method for determining a metric for non-sustained arrhythmic event | |
US6775571B1 (en) | Dynamic control of overdrive pacing based on degree of randomness within heart rate | |
WO2012058398A1 (en) | Method and apparatus for reducing noise in a medical device | |
US6766194B1 (en) | Dynamic control of overdrive pacing based on degree of randomness within heart rate | |
US10589101B2 (en) | System and method for detecting tamponade | |
US11759647B2 (en) | Medical device and method for power reduction for arrhythmia detection | |
US6694188B1 (en) | Dynamic control of overdrive pacing based on degree of randomness within heart rate | |
CN112292178A (en) | Delivery of cardiac pacing therapy for cardiac remodeling | |
CN116685258A (en) | Apparatus and method for detecting atrial tachyarrhythmia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060707 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR LV MK YU |
|
DAX | Request for extension of the european patent (deleted) | ||
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MEDTRONIC, INC. |
|
17Q | First examination report despatched |
Effective date: 20080219 |
|
RTI1 | Title (correction) |
Free format text: APPARATUS FOR MODIFYING DELIVERY OF A THERAPY IN RESPONSE TO ONSET OF SLEEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602004020804 Country of ref document: DE Date of ref document: 20090604 Kind code of ref document: P |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090802 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090822 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090822 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090722 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100125 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090722 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100701 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20091201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091201 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091231 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090723 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091023 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090422 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20211109 Year of fee payment: 18 Ref country code: FR Payment date: 20211109 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004020804 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221231 |